Oculis (NASDAQ:OCS – Get Free Report) and Forte Biosciences (NASDAQ:FBRX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.
Volatility and Risk
Oculis has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 3.23, meaning that its share price is 223% more volatile than the S&P 500.
Institutional & Insider Ownership
22.3% of Oculis shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 5.9% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oculis | 1 | 0 | 8 | 0 | 2.78 |
| Forte Biosciences | 1 | 0 | 3 | 0 | 2.50 |
Oculis currently has a consensus price target of $41.50, indicating a potential upside of 41.11%. Forte Biosciences has a consensus price target of $67.00, indicating a potential upside of 121.71%. Given Forte Biosciences’ higher possible upside, analysts plainly believe Forte Biosciences is more favorable than Oculis.
Profitability
This table compares Oculis and Forte Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oculis | -12,915.42% | -80.82% | -61.18% |
| Forte Biosciences | N/A | -75.64% | -65.94% |
Valuation and Earnings
This table compares Oculis and Forte Biosciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oculis | $780,000.00 | 1,974.99 | -$97.43 million | ($2.52) | -11.67 |
| Forte Biosciences | N/A | N/A | -$35.48 million | ($3.32) | -9.10 |
Forte Biosciences has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Forte Biosciences beats Oculis on 8 of the 13 factors compared between the two stocks.
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
About Forte Biosciences
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
